NASDAQ:GRTX Galera Therapeutics (GRTX) Stock Price, News & Analysis → Estee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI company (From Financial Markets Daily) (Ad) Free GRTX Stock Alerts $0.10 0.00 (0.00%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.10▼$0.1150-Day Range$0.10▼$0.2352-Week Range$0.09▼$3.47Volume402,396 shsAverage Volume1.57 million shsMarket Capitalization$5.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Galera Therapeutics alerts: Email Address Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Galera Therapeutics Stock (NASDAQ:GRTX)Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Read More GRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRTX Stock News HeadlinesMay 13, 2024 | globenewswire.comGalera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 3, 2024 | finanznachrichten.deGalera Therapeutics: Galera Adopts Limited Duration Stockholder Rights AgreementMay 3, 2024 | globenewswire.comGalera Adopts Limited Duration Stockholder Rights AgreementApril 1, 2024 | msn.comGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory ChallengesMarch 28, 2024 | finanznachrichten.deGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 28, 2024 | globenewswire.comGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 16, 2024 | finance.yahoo.comGRTX Apr 2024 0.500 callMarch 12, 2024 | nz.finance.yahoo.comGalera Therapeutics, Inc. (GRTX)February 27, 2024 | edition.cnn.comGalera Therapeutics, Inc.February 4, 2024 | investing.comGalera Therapeutics Inc (GRTX)February 4, 2024 | benzinga.comGalera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and DatesJanuary 21, 2024 | finance.yahoo.comGalera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17January 16, 2024 | bizjournals.comLocal publicly traded stocks lag far behind national indices in 2023January 9, 2024 | msn.comDow Tumbles Over 200 Points; US Trade Gap Narrows In NovemberNovember 28, 2023 | msn.comGalera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38November 14, 2023 | finanznachrichten.deGalera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 14, 2023 | benzinga.comGalera Therapeutics: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comGalera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 13, 2023 | benzinga.comGalera Therapeutics's Earnings OutlookNovember 1, 2023 | benzinga.comUS Stocks Fall; Pfizer Swings To Q3 LossOctober 31, 2023 | benzinga.comDow Gains 50 Points; Global Payments Posts Upbeat EarningsOctober 31, 2023 | bizjournals.comGalera Therapeutics warns of potential shutdown as it halts clinical trials and stock tanksOctober 31, 2023 | msn.comWhy Is Cancer Focused Galera Therapeutics Stock Sinking Today?October 31, 2023 | msn.comGalera plunges after citing risks to business continuityOctober 31, 2023 | finanznachrichten.deGalera Therapeutics: Galera Announces Receipt of Type A Meeting Minutes and Strategic UpdateSee More Headlines Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/14/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GRTX CUSIPN/A CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,080,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-138.81% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.41) per share Price / Book-0.04Miscellaneous Outstanding Shares54,390,000Free Float50,639,000Market Cap$5.22 million OptionableOptionable Beta2.04 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. J. Mel Sorensen M.D. (Age 67)CEO, President & Director Comp: $632.64kDr. Robert A. Beardsley M.B.A. (Age 62)Ph.D., Co-Founder & COO Comp: $464.59kMr. Christopher Degnan (Age 44)Chief Financial Officer Comp: $474.05kMs. Jennifer Evans Stacey Esq. (Age 59)Chief Legal & Compliance Officer and Secretary Ms. Andie CollierChief Regulatory & Quality Affairs OfficerMs. Judy SchnyderSenior Vice President of Clinical Operations & Data ManagementMore ExecutivesKey CompetitorsLannettNYSE:LCIRenovoRxNASDAQ:RNXTTherapeuticsMDNASDAQ:TXMDViracta TherapeuticsNASDAQ:VIRXIterum TherapeuticsNASDAQ:ITRMView All CompetitorsInstitutional OwnershipGSA Capital Partners LLPSold 259,934 shares on 5/3/2024Ownership: 6.679%View All Institutional Transactions GRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Galera Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" GRTX shares. View GRTX analyst ratings or view top-rated stocks. How have GRTX shares performed in 2024? Galera Therapeutics' stock was trading at $0.1454 at the beginning of the year. Since then, GRTX shares have decreased by 34.0% and is now trading at $0.0960. View the best growth stocks for 2024 here. Are investors shorting Galera Therapeutics? Galera Therapeutics saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 1,910,000 shares, a decrease of 9.9% from the May 15th total of 2,120,000 shares. Based on an average trading volume of 1,800,000 shares, the short-interest ratio is currently 1.1 days. Approximately 5.5% of the company's stock are sold short. View Galera Therapeutics' Short Interest. When is Galera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our GRTX earnings forecast. How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.08) EPS for the quarter. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV). When did Galera Therapeutics IPO? Galera Therapeutics (GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager. Who are Galera Therapeutics' major shareholders? Galera Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include GSA Capital Partners LLP (6.68%). Insiders that own company stock include Chris Degnan, Linda West, Mark Bachleda and Mel Sorensen. View institutional ownership trends. How do I buy shares of Galera Therapeutics? Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRTX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.